PLoS ONE · 2012 · 16 citations · 48 references
MedicineDermatologyOncologyGene Expression AnalysisMetastasisMolecular OncologyCancer BiomarkersExpression Signature DiscoveryMelanocytic TumorsMolecular Tumor ProfilingStaging Of Skin CancerTumor ClassificationCancer Metastasis BiomarkersCox RegressionCutaneous Melanoma StagingGene Expression SignaturesMelanoma BiomarkersMelanoma ClassificationPrognosis Of Cutaneous MetastasesTumor Profiling
BACKGROUND: Current prognostic clinical and morphological parameters are insufficient to accurately predict metastasis in individual melanoma patients. Several studies have described gene expression signatures to predict survival or metastasis of primary melanoma patients, however the reproducibility among these studies is disappointingly low. METHODOLOGY/PRINCIPAL FINDINGS: We followed extended REMARK/Gould Rothberg criteria to identify gene sets predictive for metastasis in patients with primary cutaneous melanoma. For class comparison, gene expression data from 116 patients with clinical stage I/II (no metastasis) and 72 with III/IV primary melanoma (with metastasis) at time of first diagnosis were used. Significance analysis of microarrays identified the top 50 differentially expressed genes. In an independent data set from a second cohort of 28 primary melanoma patients, these genes were analyzed by multivariate Cox regression analysis and leave-one-out cross validation for association with development of metastatic disease. In a multivariate Cox regression analysis, expression of the genes Ena/vasodilator-stimulated phosphoprotein-like (EVL) and CD24 antigen gave the best predictive value (p = 0.001; p = 0.017, respectively). A multivariate Cox proportional hazards model revealed these genes as a potential independent predictor, which may possibly add (both p = 0.01) to the predictive value of the most important morphological indicator, Breslow depth. CONCLUSION/SIGNIFICANCE: Combination of molecular with morphological information may potentially enable an improved prediction of metastasis in primary melanoma patients. A strength of the gene expression set is the small number of genes, which should allow easy reevaluation in independent data sets and adequately designed clinical trials.
48
Cancer: Principles and Practice of Oncology.
Annals of Internal Medicine · 1991 · 8.5K citations
Medicine, Oncology, Oncology Nursing +10
Cancer Incidence in Five Continents
Richard Doll, C. S. Muir, John A. H. Waterhouse · 1970 · 8.5K citations
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text